[go: up one dir, main page]

MX2024005063A - Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos. - Google Patents

Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.

Info

Publication number
MX2024005063A
MX2024005063A MX2024005063A MX2024005063A MX2024005063A MX 2024005063 A MX2024005063 A MX 2024005063A MX 2024005063 A MX2024005063 A MX 2024005063A MX 2024005063 A MX2024005063 A MX 2024005063A MX 2024005063 A MX2024005063 A MX 2024005063A
Authority
MX
Mexico
Prior art keywords
sup
spirotricycle
methods
ripk1
inhibitors
Prior art date
Application number
MX2024005063A
Other languages
English (en)
Inventor
Xavier Fradera
Phieng Siliphaivanh
Zachary G Brill
Duque Jenny Lorena Rico
Abdelghani Abe Achab
Joey L Methot
Jing Su
Brandon A Vara
Erin F Dimauro
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2024005063A publication Critical patent/MX2024005063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En el presente documento se describen compuestos de Fórmula I: (ver Fórmula) I o una sal farmacéuticamente aceptable del mismo, en donde A, R1, R2, R3, W, X, Y, Z, m, n y p son como se definen en el presente documento. Los compuestos de Fórmula I actúan como inhibidores de RIPK1 y pueden ser útiles en la prevención, el tratamiento o la actuación como agente curativo para enfermedades relacionadas con RIPK1.
MX2024005063A 2021-10-27 2022-10-25 Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos. MX2024005063A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272276P 2021-10-27 2021-10-27
US202263407851P 2022-09-19 2022-09-19
PCT/US2022/047657 WO2023076218A1 (en) 2021-10-27 2022-10-25 Spirotricycle ripk1 inhibitors and methods of uses thereof

Publications (1)

Publication Number Publication Date
MX2024005063A true MX2024005063A (es) 2024-05-13

Family

ID=84364239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005063A MX2024005063A (es) 2021-10-27 2022-10-25 Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.

Country Status (9)

Country Link
US (1) US12180226B2 (es)
EP (1) EP4423096A1 (es)
JP (1) JP2024541944A (es)
KR (1) KR20240089062A (es)
AU (1) AU2022379477A1 (es)
CA (1) CA3236550A1 (es)
MX (1) MX2024005063A (es)
TW (1) TW202334166A (es)
WO (1) WO2023076218A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096697A1 (en) * 2023-11-02 2025-05-08 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63203B1 (sr) * 2016-12-09 2022-06-30 Denali Therapeutics Inc Jedinjenja korisna kao inhibitori ripk1

Also Published As

Publication number Publication date
EP4423096A1 (en) 2024-09-04
US20230159558A1 (en) 2023-05-25
JP2024541944A (ja) 2024-11-13
US12180226B2 (en) 2024-12-31
WO2023076218A1 (en) 2023-05-04
KR20240089062A (ko) 2024-06-20
TW202334166A (zh) 2023-09-01
AU2022379477A1 (en) 2024-05-02
CA3236550A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
ZA202212095B (en) Il4i1 inhibitors and methods of use
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
EP4628490A3 (en) Nlrp3 inflammasome inhibitors
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
WO2024123913A8 (en) Kras(g12v) inhibitors
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
PH12012501386A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
CL2023001367A1 (es) Inhibidores de btk
PH12022550124A1 (en) Enzyme inhibitors
MX2024003772A (es) Compuestos de imidazopiridazina inhibidores de il-17.
MX2024013095A (es) Compuestos inhibidores de fgfr2
MX2024003770A (es) Compuestos de imidazopiridazina inhibidores de il-17.
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
MX2024001352A (es) Inhibidor novedoso de la poli(adp-ribosa) polimerasa y uso del mismo.
GB0314967D0 (en) Piperazine derivatives
MX2024003475A (es) Polimorfos como inhibidores de erbb.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
MX2022002069A (es) Inhibidores de enzimas.
SE0302756D0 (sv) Novel Compounds
MX2023009677A (es) Inhibidores de enzimas.
MX2024005063A (es) Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.
MX2025013372A (es) Inhibidores de gsk3\03b1 y metodos de uso de estos